/QNRX
QNRX Stock - Quoin Pharmaceuticals, Ltd.
Healthcare|BiotechnologyNASDAQ
$14.20+2.75%
+$0.38 (+2.75%) • Dec 19
63
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.77
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.45
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $15.62
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for QNRX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$14.06 – $14.34
TARGET (TP)$16.33
STOP LOSS$13.06
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.87
52W High$41.80
52W Low$5.01
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-9,528,465 | $-9,378,504 | $-9,257,704 | $-6,062,850 | $-1,670,010 |
| Net Income | $-8,962,472 | $-8,686,573 | $-9,381,496 | $-21,462,588 | $-2,095,364 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-66.85 | $-337.47 | $-22.97 | $-28543.20 | $-88.10 |
Company Overview
Quoin Pharmaceuticals, Ltd., a specialty pharmaceutical company, focuses on the development of therapeutic products for rare and orphan diseases. The company's lead product is QRX003, a topical lotion to treat Netherton Syndrome. It also develops QRX004 for the treatment dystrophic epidermolysis bullosa; and QRX006, a therapy to treat rare skin disease. The company is based in Ashburn, Virginia.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
QNRXBeat Rate
31%
Last 16 quarters
Avg Surprise
-2515.7%
EPS vs Estimate
Beats / Misses
5/11
Last 12 quarters
Latest EPS
$-6.71
Q4 2025
EPS Surprise History
Q1 24
+12.2%
$-72.73vs$-82.87
Q2 24
-5006.6%
$-38.81vs$-0.76
Q3 24
+48.0%
$-13.64vs$-26.22
Q4 24
-6.8%
$-16.43vs$-15.38
Q1 25
-2348.0%
$-12.24vs$-0.50
Q2 25
-68.8%
$-6.50vs$-3.85
Q3 25
+8.1%
$-6.28vs$-6.83
Q4 25
-5.5%
$-6.71vs$-6.36
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 11, 2026 | — | — | — | — |
Q1 2026 | Mar 12, 2026 | $-6.42 | — | — | — |
Q4 2025 | Nov 6, 2025 | $-6.36 | $-6.71 | -5.5% | ✗ MISS |
Q3 2025 | Aug 7, 2025 | $-6.83 | $-6.28 | +8.1% | ✓ BEAT |
Q2 2025 | May 13, 2025 | $-3.85 | $-6.50 | -68.8% | ✗ MISS |
Q1 2025 | Mar 13, 2025 | $-0.50 | $-12.24 | -2348.0% | ✗ MISS |
Q4 2024 | Nov 7, 2024 | $-15.38 | $-16.43 | -6.8% | ✗ MISS |
Q3 2024 | Aug 8, 2024 | $-26.22 | $-13.64 | +48.0% | ✓ BEAT |
Q2 2024 | May 9, 2024 | $-0.76 | $-38.81 | -5006.6% | ✗ MISS |
Q1 2024 | Mar 13, 2024 | $-82.87 | $-72.73 | +12.2% | ✓ BEAT |
Q4 2023 | Nov 8, 2023 | $-83.92 | $-68.18 | +18.8% | ✓ BEAT |
Q3 2023 | Aug 2, 2023 | $-2.82 | $-74.48 | -2541.1% | ✗ MISS |
Q2 2023 | May 8, 2023 | $-109.13 | $-142.71 | -30.8% | ✗ MISS |
Q1 2023 | Mar 8, 2023 | $0.62 | $-172.10 | -27858.1% | ✗ MISS |
Q4 2022 | Nov 10, 2022 | $-1217.27 | $-394.56 | +67.6% | ✓ BEAT |
Q3 2022 | Aug 18, 2022 | $-3.08 | $-13.60 | -341.6% | ✗ MISS |
Q2 2022 | Apr 13, 2022 | $-8.81 | $-21.27 | -141.5% | ✗ MISS |
Q4 2021 | Dec 31, 2021 | — | $-949.32 | — | — |
Q4 2021 | Dec 17, 2021 | $-3.25 | $-70.11 | -2057.2% | ✗ MISS |
Q3 2021 | Aug 24, 2021 | — | $-216.57 | — | — |
Latest News
Quoin Pharmaceuticals shares are trading higher after the company said target loading concentrations were successfully achieved for its two topical rapamycin delivery technologies.
📈 PositiveBenzinga•Nov 11, 2025, 02:44 PM
Quoin Pharmaceuticals Announces Achieves Target Loading Concentration For Its Two Topical Rapamycin Delivery Technologies.
📈 PositiveBenzinga•Nov 11, 2025, 01:34 PM
Quoin Pharmaceuticals Files For Offering Of Up To 10.05M ADSs
📉 NegativeBenzinga•Nov 7, 2025, 09:58 PM
Quoin Pharmaceuticals Q3 EPS $(6.71) Misses $(6.50) Estimate
📉 NegativeBenzinga•Nov 6, 2025, 01:34 PM
Quoin Pharmaceuticals Announces Recruitment Of Three Additional Pediatric Patients For Its Investigator-Led Netherton Syndrome Study And Reports 9-month Results From The First Patient Treated With QRX003 Showing Completely Healed Skin After 9 Months Of 'Whole Body' Treatment
📈 PositiveBenzinga•Oct 28, 2025, 12:34 PM
Quoin Pharmaceuticals Announces FDA Orphan Drug Designation For QRX003 In Netherton Syndrome
📈 PositiveBenzinga•Oct 21, 2025, 12:31 PM
Quoin Pharmaceuticals Shares Halted On Circuit Breaker To The Upside, Stock Now Up 412.25%
📈 PositiveBenzinga•Oct 10, 2025, 02:45 PM
Quoin Pharmaceuticals Shares Resume Trade, Then Halted Again On Circuit Breaker To The Upside, Stock Now Up 169.61%
📈 PositiveBenzinga•Oct 10, 2025, 02:08 PM
Quoin Pharmaceuticals Shares Halted On Circuit Breaker To The Upside, Stock Now Up 135.91%
📈 PositiveBenzinga•Oct 10, 2025, 02:03 PM
Quoin Pharmaceuticals Shares Resume Trade
➖ NeutralBenzinga•Oct 10, 2025, 02:01 PM
Quoin Pharmaceuticals Shares Halted On Circuit Breaker To The Upside, Stock Now Up 88.24%
📈 PositiveBenzinga•Oct 10, 2025, 01:54 PM
Quoin Pharmaceuticals shares are trading higher. The company announced a $104.5 million private placement.
📈 PositiveBenzinga•Oct 10, 2025, 01:34 PM
Quoin Pharma Announces $104.5M Private Placement, Including $16.5M Upfront and $88M In Warrant-Linked Upside Priced Above Prior Close
📈 PositiveBenzinga•Oct 10, 2025, 01:27 PM
Quoin Pharmaceuticals Appoints Sally Lawlor As CFO
➖ NeutralBenzinga•Aug 18, 2025, 12:35 PM
Frequently Asked Questions about QNRX
What is QNRX's current stock price?
Quoin Pharmaceuticals, Ltd. (QNRX) is currently trading at $14.20 per share. The stock has moved +2.75% today.
What is the analyst price target for QNRX?
No analyst price targets are currently available for this stock.
What sector is Quoin Pharmaceuticals, Ltd. in?
Quoin Pharmaceuticals, Ltd. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is QNRX's market cap?
Quoin Pharmaceuticals, Ltd. has a market capitalization of $0.01 billion, making it a small-cap company.
Does QNRX pay dividends?
No, Quoin Pharmaceuticals, Ltd. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorCYCN
Cyclerion Therapeutics, Inc.
$1.45
Mkt Cap: $0.0B
KTTA
Pasithea Therapeutics Corp.
$1.16
Mkt Cap: $0.0B
NBY
NovaBay Pharmaceuticals, Inc.
$5.30
Mkt Cap: $0.0B
PLRZ
Polyrizon Ltd.
$9.43
Mkt Cap: $0.0B
PMCB
PharmaCyte Biotech, Inc.
$0.86
Mkt Cap: $0.0B
RADX
Radiopharm Theranostics Limited
$5.19
Mkt Cap: $0.0B
TCRT
Alaunos Therapeutics, Inc.
$3.56
Mkt Cap: $0.0B
VIVS
VivoSim Labs, Inc.
$1.98
Mkt Cap: $0.0B
VYNE
VYNE Therapeutics Inc.
$0.59
Mkt Cap: $0.0B
XTLB
XTL Biopharmaceuticals Ltd.
$0.82
Mkt Cap: $0.0B
Explore stocks similar to QNRX for comparison